ORMOND BEACH, Fla., September 23, 2026 — Germfree, a full-lifecycle engineering and manufacturing partner for mission-critical environments across life sciences, healthcare and biocontainment, today announced the appointment of Adam Simon as Chief Financial Officer and Geoffrey Schwartz as Chief Commercial Officer, alongside a refreshed brand identity and redesigned Germfree.com. Together, Simon and Schwartz add two capabilities central to Germfree’s growth: the financial and operating architecture required to scale a more sophisticated enterprise, and the commercial leadership required to stay closely connected to customers and markets.

The moves reflect a broader evolution underway at Germfree as the company builds for its next era of growth. Simon will focus on building the financial and operating infrastructure required for the company’s next stage — moving Germfree toward greater enterprise-level discipline and creating a scalable platform capable of supporting both organic growth and, over time, a broader portfolio of complementary businesses. Schwartz will help deepen Germfree’s customer and market strategy as the company expands its role as a strategic partner across life sciences and healthcare.

Across advanced therapies, biomanufacturing, hospital and compounding pharmacy, and high-containment applications, customers are navigating increasingly complex requirements and seeking partners capable of taking greater accountability across critical infrastructure, equipment and lifecycle support.

Germfree’s refreshed tagline, Made for Mission Critical, puts language around the role the company has played since 1962 designing, building and supporting environments where safety, reliability and execution matter.

As part of that evolution, Germfree has strengthened its executive leadership team with two leaders whose experience directly supports the company’s next phase.

Simon joins Germfree as Chief Financial Officer after serving as Senior Vice President of Finance at regenerative medicine company StimLabs, following 15 years serving private equity portfolio and family owned businesses at PwC. He brings a combination of financial rigor, operating experience and life sciences industry knowledge.

“Germfree has significant opportunity ahead and realizing that opportunity requires us to build for the company we intend to become, not simply the company we are today,” said Simon. “My focus is on creating the financial discipline, operating infrastructure and visibility needed to scale the enterprise responsibly and support its continued evolution.”

Schwartz joins Germfree as Chief Commercial Officer with nearly three decades of life sciences leadership experience. Most recently, he served as CEO and General Manager of Mirus Bio and previously as the company’s Chief Commercial Officer, including through its acquisition by MilliporeSigma.

“Our customers are solving increasingly complex problems and need partners who understand how facilities, equipment, process and lifecycle support come together,” said Schwartz. “Germfree has the opportunity to bring those capabilities together in a highly differentiated way, and I am excited to help build that future.”

Ormond Beach, FL, September 9, 2026 — Germfree Laboratories, LLC, a pioneering leader in modular and mobile cleanroom infrastructure, today announced the certified integration of its Smarthood sterile compounding hood with Wolters Kluwer Health’s Simplifi+® IV Workflow Management with Assure-Trak® and Simplifi 797® solutions. The integration includes full hardware and software compatibility for highly accurate measurements with both volumetric and gravimetric workflows, allowing pharmacy teams to complete required workflow steps without leaving the sterile field to reduce inefficiencies and contamination risk.

The adoption of IV workflow automation has been critical for improving the safety of hospital pharmacies. Since its launch, Germfree’s Smarthood has set the industry benchmark for streamlined integration of the hardware pharmacy teams rely on the most, including cameras, scales, barcode scanners, and more, directly into the hood itself. Paired with Simplifi+, Wolters Kluwer’s software for standardizing operations and automating compliance, the integration enables full inside-the-hood operations while eliminating manual workflows, helping pharmacy teams complete preparations more efficiently while maintaining continuous audit readiness.

“By integrating Germfree’s innovative hardware with Simplifi+, we’re bringing greater precision and confidence directly into the sterile compounding environment,” said Christopher Sullivan, Vice President and General Manager, Pharmacy and Health Technology Solutions, at Wolters Kluwer Health. “This helps  pharmacy teams work more efficiently, strengthen traceability, and ultimately support safer patient care.”

By pairing Smarthood’s built-in field-of-view camera with Simplifi+ IV Workflow, the integration delivers a new level of video documentation. Simplifi+ is the first software to record field-of-view video during preparation and associate that footage directly with the individual preparation record, giving teams greater visibility into the compounding process and stronger confidence in every record.

Ormond Beach, FL, August 19, 2026 — Germfree, a pioneering leader in modular cleanroom infrastructure and services, and Nuvai Medical Technologies, a pioneer in technologies for the safe, accurate, and precise preparation of medications in the clinical setting, announced a partnership to integrate Nuvai’s Aseptique AI-powered aseptic monitoring platform into Germfree’s Smarthood, providing hospital pharmacies with real-time visibility into compounding technique using the system’s existing cameras. These capabilities will move oversight of aseptic handling from simulations and retrospective microbe testing to real-time monitoring.

The integration adds a new layer of protection to IV compounding, without requiring additional hardware. Traditionally, pharmacies rely on periodic assessments of aseptic technique to meet the requirements of pharmaceutical guidelines and ensure the safety of compounded medicines. By utilizing Aseptique, pharmacies can move from indirectly monitoring the safety of an environment to directly ensuring the use of appropriate aseptic technique.

“By combining Smarthood with Aseptique, we are extending the value of a platform our customers already trust,” said Judd Baker, Vice President of Healthcare at Germfree. “Together, we are giving pharmacy teams actionable insight into aseptic technique and helping strengthen the safety and consistency of IV compounding.”

The integration will help pharmacy teams gain greater confidence that sterile preparations are produced consistently while building on the workflow they already use. Each technician receives an individual dashboard highlighting aseptic technique deviations, while pharmacy leaders gain an enterprise-wide view of performance trends. The combined solution supports continuous improvement, reduces the risk of compounding errors, and helps reinforce best practices across the department.

“Nuvai Medical Technologies is excited to integrate our Aseptique platform into the Germfree Smarthood. Aseptique leverages machine learning to ensure every compounded product meets the highest sterility standards. Partnering with Germfree allows us to bring essential innovation to pharmacy operations, strengthening patient safety and supporting pharmacy teams in preparing IV medications accurately,” said Stephen Eckel, Founder and President of Nuvai Medical Technologies.

Ormond Beach, FL, March 24, 2026 — Germfree Laboratories (“Germfree”), a leading provider of integrated cGMP infrastructure, equipment, and services for advanced therapies and hospital manufacturing, today announced the appointment of Carol Houts as Chief Executive Officer. Kevin Kyle, Germfree’s previous CEO, will transition to an advisory role with Germfree and EW Healthcare Partners.

Carol brings 30 years of healthcare and life sciences experience to the role, with a career spanning clinical development, global regulatory strategy, cGMP operations, quality systems, and commercial leadership at organizations including Pfizer, Stryker Biotech, and CROs executing clinical trials globally. At Germfree, she has been serving as Chief Commercial & Strategy Officer and member of the Board, where she has helped shape the company’s strategic growth agenda and expand its partnerships across pharmaceutical and healthcare markets. During her tenure, she has led key commercial initiatives across decentralized manufacturing, global partnerships, and the company’s expanding solutions portfolio, including pharmaceutical isolators, Smarthood IV workflow systems, and mobile and modular GMP platforms.

As CEO, Carol will focus on strengthening execution, operational performance, and scaling Germfree’s services capabilities to support a growing global customer base. With the commercial launch of Smarthood and increasing demand for Germfree’s isolator and modular GMP solutions, the company is entering a significant new phase of growth. Germfree is currently delivering some of its most complex turnkey programs to date, including purpose-built ATMP manufacturing solutions designed to be operationally ready from day one.

“What we have built at Germfree, the partnerships, the platform, and the pipeline puts us in a strong position to lead this industry forward,” said Carol Houts, Chief Executive Officer of Germfree Laboratories. “My focus is on deepening the customer relationships at our core, relentless focus on execution, and scaling our services capabilities across the full portfolio from advanced therapy manufacturing to hospital pharmacy and beyond.”

“We are excited to have Carol at the helm of Germfree,” said Evis Hursever, Ph.D., Chief Executive Officer of EW Healthcare Partners. “Over nearly a decade, she has been at the center of Germfree’s commercial growth, helping build the partnerships, platform, and pipeline that define the company today. She brings the operational discipline and strategic clarity needed to scale the business, making her the ideal choice to lead the company as it enters this next phase of growth. EW Healthcare Partners is fully committed to supporting Germfree’s ambitious plans.”

“The board and I are thrilled to welcome Carol as Germfree’s CEO,” said Andy Thomson, Chair of the Board of Germfree and Operating Partners with EW Healthcare Partners. “Carol is a seasoned global healthcare executive who brings tremendous experience and knowledge in commercial and operation excellence. Her expertise and leadership will be critical in successfully executing the ambitious commercial and operational plan as Germfree strives in its mission as the partner of choice in the manufacturing of advanced therapies.”